Wells Fargo & Company Has Lowered Expectations for Avantor (NYSE:AVTR) Stock Price

Avantor (NYSE:AVTR) had its price objective dropped by equities research analysts at Wells Fargo & Company from $28.00 to $25.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective suggests a potential upside of 35.76% from the company’s current price.

A number of other equities analysts have also weighed in on AVTR. Stifel Nicolaus reduced their target price on shares of Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Monday. Robert W. Baird reduced their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. UBS Group reiterated a “neutral” rating and issued a $25.00 price objective (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Barclays reduced their target price on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Monday. Finally, Raymond James lowered their price target on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $26.15.

Avantor Stock Performance

Shares of Avantor stock opened at $18.42 on Monday. Avantor has a 12 month low of $18.19 and a 12 month high of $28.00. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $12.53 billion, a PE ratio of 40.03, a PEG ratio of 3.87 and a beta of 1.28. The stock’s fifty day simple moving average is $21.68 and its 200 day simple moving average is $23.44.

Avantor (NYSE:AVTR) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a return on equity of 12.24% and a net margin of 4.54%. During the same quarter in the previous year, the firm posted $0.22 EPS. On average, research analysts predict that Avantor will post 0.98 EPS for the current year.

Hedge Funds Weigh In On Avantor

Large investors have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB grew its stake in Avantor by 99.5% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock valued at $26,000 after buying an additional 625 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Avantor by 106.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock worth $34,000 after acquiring an additional 830 shares during the period. UMB Bank n.a. acquired a new position in shares of Avantor in the third quarter valued at approximately $49,000. Global Retirement Partners LLC increased its stake in shares of Avantor by 76.7% during the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock worth $52,000 after purchasing an additional 1,067 shares during the period. Finally, Nisa Investment Advisors LLC lifted its holdings in Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after purchasing an additional 835 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.